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Staphylococcus aureus skin colonization is universal
in atopic dermatitis and common in cancer patients
treated with epidermal growth factor receptor
inhibitors. However, the causal relationship of
dysbiosis and eczema has yet to be clarified.
Herein, we demonstrate that Adam17fl/flSox9-Cre
mice, generated to model ADAM17-deficiency in
human, developed eczematous dermatitis with natu-
rally occurring dysbiosis, similar to that observed
in atopic dermatitis. Corynebacterium mastitidis,
S. aureus, and Corynebacterium bovis sequentially
emerged during the onset of eczematous dermatitis,
and antibiotics specific for these bacterial species
almost completely reverseddysbiosis and eliminated
skin inflammation. Whereas S. aureus prominently
drove eczema formation, C. bovis induced robust
T helper 2 cell responses. Langerhans cells were
required for eliciting immune responses against
S. aureus inoculation. These results characterize
differential contributions of dysbiotic flora during
eczema formation, and highlight the microbiota-
host immunity axis as a possible target for future
therapeutics in eczematous dermatitis.
INTRODUCTION
Microbiome analyses in recent years have revealed that
mammalian body surfaces are colonized by vast numbers of
bacterial communities (Grice et al., 2009), providing impetus to
explore the roles of the microbiota in normal and diseased
skin. Staphylococcus aureus has long been known to heavily
colonize skin of patients with atopic dermatitis (AD) (Leyden
et al., 1974), a chronic inflammatory skin disease that develops
in individuals with barrier-disrupted skin, and that leads to the
progressive development of asthma and food allergy referred
to as the atopic march (Spergel and Paller, 2003). Microbiome
analysis has revealed temporal dybiosis dominated by
S. aureus during AD flares (Kong et al., 2012), suggesting an756 Immunity 42, 756–766, April 21, 2015 ª2015 Elsevier Inc.important role of S. aureus and/or dysbiosis during active atopic
inflammation.
A major cause for stratum corneum barrier disruption in AD is
attributed to loss-of-function mutations in FLG that encodes fi-
laggrin, a structural protein in keratinocytes and corneocytes,
thereby allowing outside-in penetration of foreign antigens and
subsequent sensitization (Irvine et al., 2011). Other rare genetic
diseases also manifest eczematous dermatitis that are clinically
nearly identical to AD and could represent prototypic eczema
with defects in relatively well-characterized genes (Kubo et al.,
2012). Among such diseases are Netherton syndrome and hyper
immunoglobulin E (IgE) syndrome, resulting from mutations in
SPINK5 and STAT3, respectively (Chavanas et al., 2000; Mine-
gishi et al., 2007). S. aureus is commonly isolated from skin in
both of these diseases, and microbiome analysis has revealed
dysbiosis with overrepresentation of S. aureus and Corynebac-
terium species in inflammatory skin lesions of hyper IgE syn-
drome (Oh et al., 2013).
Further supporting the possible involvement of dysbiosis
in eczema pathophysiology, dysbiosis is implicated in other
inflammatory skin conditions. Cancer patients treated with
epidermal growth factor receptor (EGFR) inhibitors commonly
develop eczematous rashes and pustules (Lacouture, 2006),
from which S. aureus can be isolated (Eilers et al., 2010; Lich-
tenberger et al., 2013). Despite its apparent association
with eczematous inflammation in AD, genetic diseases and
EGFR inhibitor usage, the cause-or-effect relationship of dys-
biosis and AD or eczematous dermatitis has not been deter-
mined to date. Addressing this issue would require a mouse
model in which the microbiota alterations recapitulate human
conditions.
A disintegrin and metalloproteinase 17 (ADAM17) is a trans-
membrane protease that cleaves a variety of membrane-bound
proteins to release soluble forms (Blobel, 2005). ADAM17 plays
a major role in tumor necrosis factor alpha (TNF-a) and EGFR
signaling pathways, in which pro-TNF-a and pro-EGFR ligands
are shed by ADAM17 from cell surfaces into active forms (Blobel,
2005). Genomic ablation of Adam17 in mice leads to perinatal
lethality (Peschon et al., 1998). ADAM17 deficiency has been
recently identified in humans (Blaydon et al., 2011), defining a
new genetic disorder. Importantly, described patients exhibited
eczematous dermatitis and pustular lesions and were prone to
S. aureus infections.
Figure 1. Eczematous Inflammation in ADAM17-Deficient Skin
(A) Histopathology of skin biopsy from WT and Adam17fl/fl Sox9-Cre
(Adam17DSox9) mice. Scale bars represent 50 mm.
(B–D) TEWL, serum IgE and serum CCL17/TARC values in WT and
Adam17DSox9 mice (N = 8).
(E) Flow cytometry analysis of IFN-g, IL-4, and IL-17A production in CD4+ cells
from lymph nodes, and (F and G) IL-17A and IL-22 production by CD3+ cells in
epidermis of WT and Adam17DSox9 mice (N = 8). TCRgdhigh cells represent
dendritic epidermal T cells, and TCRgdmid cells represent gd T cells that have
infiltrated epidermis from the dermis. Data in (B)(G) are shown asmean ± SD.
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 as determined by Student’s
t test. See also Figure S1.Herein, we show that mice lacking Adam17 in Sox9-express-
ing tissues including epidermis (Adam17fl/flSox9-Cre mice)
manifested phenotypes similar to their human counterparts, ex-
hibiting eczematous skin with disrupted barriers, elevated serum
IgE and mixed T helper cell responses. Microbiome analysis of
eczematous lesions in these mice revealed prominent dysbiosis
that recapitulated that in human AD and eczematous derma-
titis. We also demonstrate that eczematous inflammation in
Adam17fl/flSox9-Cre mice was driven by dysbiosis, in which
S. aureus and C. bovis contribute differentially; that dysbiosis
could be induced by targeted ablation of EGFR signaling;
and that epidermal Langerhans cells mediate early immune re-
sponses to S. aureus.
RESULTS
Adam17fl/flSox9-Cre Mice Exhibit Eczematous
Inflammation
We generated mice that lack Adam17 in Sox9-expressing tis-
sues including epidermis (Adam17fl/flSox9-Cre mice; henceforth
referred to asAdam17DSox9 mice) initially to study ADAM17 func-
tion in bones (Horiuchi et al., 2009) and hair follicles (Nagao et al.,
2012). While Sox9 is expressed in a variety of tissues including
lung, pancreas, brain, gut, and kidneys, its expression in skin is
mostly limited to the epidermal component (Horiuchi et al.,
2009).
Consistent with previous reports that utilized mice expressing
Cre recombinase driven by the keratin 14 promoter to ablate
Adam17 (Franzke et al., 2012; Murthy et al., 2012), Adam17DSox9
mice exhibited dry skin around 3 weeks after birth, which pro-
gressed to eczematous lesions with intense pruritus (Figure S1A,
Movie S1), recapitulating symptoms reported in patients with
ADAM17 mutation (Blaydon et al., 2011). Lesional skin biopsies
revealed mononuclear cell infiltrates including lymphocytes and
mast cells (Figures 1A and S1B). Increased transepidermal water
loss (TEWL) indicated barrier dysfunction (Figure 1B). Serum IgE
and CCL17, the latter a T helper 2 (Th2) cell chemokine that re-
flects disease activity in human AD (Kakinuma et al., 2001),
were elevated (Figures 1C and 1D).
Barrier disruption, eczema, and the mixture of humoral and
cellular inflammation observed in Adam17DSox9 mice closely
resembled features of human AD and genetic diseases that
mimic AD. Owing to their unimpaired survival rate, these
mice were advantageous over previously reported mice with
Adam17 ablated in Keratin 14-expressing tissues (Franzke
et al., 2012).
Consistent with the eczematous phenotype, cytokine expres-
sion analysis via flow cytometry in skin draining lymph nodes
revealed increases in the numbers of Th1 and Th2 cells and
prominent increases in Th17 cells (Figure 1E). Epidermal T cell
composition was strikingly altered. Dendritic epidermal T cells,
a resident Vg5+ gd T cell subset in epidermis, were replaced by
the massive infiltration of Vg5neg gd TCRmid T cells and CD4+
T cells (Figure 1F). Approximately 20% of Vg5neg gd TCRmid
T cells expressed Vg4, but the majority did not (data not shown).
Cytokine analysis of infiltrating T cells revealed that epidermal
CD4 T cells consisted of Th17 and Th22 cells, and the majority
of Vg5neg gd TCRmid T cells produced interleukin-17 (IL-17)
(gdT17), a fraction of which also produced IL-22 (Figure 1G).Immunity 42, 756–766, April 21, 2015 ª2015 Elsevier Inc. 757
Figure 2. Staphylococcus aureus-Associated Dysbiosis in Adam17DSox9 Mouse Skin
(A and B) Quantification of S. aureus cultured from facial skin swab samples of WT and Adam17DSox9 mice (N = 8, mean ± SD).
(C) Scanning electron microscopy on skin surface of WT and Adam17DSox9 mice. Scale bars represent 10 mm.
(D) Microbiota of WT and Adam17DSox9 mice analyzed at indicated time points after birth. Relative abundance of order-genera that represented >1% of total 16S
rRNA gene sequences with additional speciation of Corynebacterium and Staphylococcus genus. Results represent two independent experiments (N = 3). See
also Figure S2.In addition to Th1 and Th2 responses in AD, emerging reports
demonstrate the contributions of Th17 and Th22 (Gittler et al.,
2012; Koga et al., 2008; Nograles et al., 2009; Sua´rez-Farin˜as
et al., 2013), suggesting that immune responses in AD are com-
plex. Relative contributions of T helper subpopulations have not
been explored in depth, but the prominent IL-17 responses in
Adam17DSox9 mice seemed atypical in the context of eczema-
tous dermatitis. To investigate the role of IL-17 and its associated
cytokine IL-23, both of which are important in psoriatic inflam-
mation, we crossed Adam17DSox9 mice to IL-17- and IL-23-defi-
cient backgrounds. The lack of each cytokine had no effect on
the onset of eczematous dermatitis (Figure S1C), demonstrating
that the phenomenon observed herein was distinct from psoria-
sis and that IL-17 responses in Adam17DSox9 mice are likely to
be secondary responses. Consistently, Adam17DSox9 mice ex-
hibited striking pruritus, dry skin and eczematous dermatitis,
elevated IgE concentrations, and a mixture of helper T cell re-
sponses, phenotypes that are remarkably similar to symptoms
generally observed in AD and eczematous dermatitis in human
genetic diseases.
Adam17DSox9 Mice Exhibit Altered Skin Microbiota
Given the resemblance of the Adam17DSox9 mice phenotype to
human eczematous dermatitis, we swabbed and cultured skin
surfaces of 8-week-old Adam17DSox9 mice and WT littermates.
Striking outgrowth of S. aureus was obtained from Adam17DSox9758 Immunity 42, 756–766, April 21, 2015 ª2015 Elsevier Inc.mice cultures, but not from WT littermates (Figure 2A). Quanti-
fying colony-forming units showed that S. aureus colonization
began 3 to 4 weeks after birth and increased thereafter (Fig-
ure 2B). Scanning electron microscopy and immunofluores-
cence microscopy revealed S. aureus within stratum corneum
and within follicular openings (Figures 2C, Figures S2A–S2C).
Recent advances in microbiome analyses have revealed that
varieties of bacterial communities inhabit mammalian body sur-
faces (Grice et al., 2009) and shape gut and skin immunity (Iva-
nov et al., 2009; Naik et al., 2012). To characterize microbiota
during the onset of eczematous inflammation, we performed mi-
crobiome analyses inWT orAdam17DSox9 mice over a period of 2
to 14 weeks after birth. We carried out 454 pyrosequencing of
the V1-V3 region of bacterial 16S rRNA genes. All WT littermate
mice exhibited identical microbiota and underwent similar
changes that began around week 8 after birth (Figure 2D),
perhaps simulating bacterial community shifts observed in
human physiologic development across Tanner stages (Oh
et al., 2012). S. aureus was extremely rare among the WT skin
microbiota.
Microbiota of Adam17DSox9 mice were indistinguishable from
WT mice at week 2 after birth but underwent dramatic changes
at week 3–4 (Figure 2D). Emergence of Corynebacterium masti-
tidis was initially observed, followed by S. aureus at approxi-
mately week 6, which appeared to coincide with the aggrava-
tion of skin symptoms (Figure S2D). Of note, C. mastitidis
disappeared and was completely replaced by Corynebacterium
bovis, immediately after the emergence of S. aureus (Figure 2D).
Therefore, the skin microbiota of Adam17DSox9 mice undergo a
sequential change where dysbiosis starts with the emergence
of C. mastitidis and with S. aureus and C. bovis predominating
later. The finding that dysbiosis includes S. aureus and Coryne-
bacterium species recapitulates that which is seen in both hu-
man eczematous dermatitis and AD.
Dysbiosis Drives Eczematous Inflammation
The above findings in Adam17DSox9 mice provided a unique op-
portunity to address the role of dysbiosis during eczematous
inflammation. On the basis of antibiotic sensitivity profiles of
S. aureus (strain SAAS9) and C. bovis (strain CBAS9) isolates
from Adam17DSox9 mice, we elected to treat Adam17DSox9
mice with cefazolin and enrofloxacin because of their anti-bacte-
rial activity against the isolated strains (Table S1), established
use in human (Schneider et al., 2013) or veterinarian clinical prac-
tice (Paradis et al., 1990), and solubility, which enabled contin-
uous feeding of mice with these antibiotics through drinking
water. After weaning, each group of Adam17DSox9 mice was
separated into cages that were given drinking water with or
without antibiotics.
In striking contrast to untreated Adam17DSox9mice, antibiotic-
treated mice were almost completely protected from develop-
ment of eczematous lesions (Figure S3A). Clinical scores,
TEWL, and serum IgE concentrations also remained lower than
their untreated controls (Figures 3A–3C). FACS analysis revealed
a reduction in the numbers of Th2 and Th17 cells in skin draining
lymph nodes (Figure 3D). Consistent with this data, serum con-
centrations of IL-1b, IL-6, IL-13, IL-17A, and IL-17F were
decreased after antibiotic treatment, although CCL17/TARC re-
mained high (Figure S3B). Antibiotics also normalized epidermal
gd T cell constituents (Figure S3C). CD4+ T cell numbers in
epidermis of antibiotic-treated Adam17DSox9 mice remained
high, but these remaining CD4+ T cells produced less IL-4 and
did not produce IL-17A or IL-22 (Figure 3E and Figure S3D). A
potential explanation is that the CD4+ T cells were attracted to
epidermis via CCL17 that remained highly expressed but were
not primed to produce cytokines owing to the decrease in
epidermal bacterial load.
Microbiome analysis revealed higher bacterial diversity in
antibiotic-treated Adam17DSox9 mice than in untreated mice,
and dramatic reductions in the proportions of S. aureus were
observed (Figures 3F and G and Figure S3E). C. bovis propor-
tions were also reduced, but to a lesser extent when compared
to the changes observed for S. aureus (Figures 3F and 3G and
Figure S3E). The bacterial community structure in untreated
Adam17DSox9 mice and controls diverged over time but was
more similar after antibiotic treatment (Figures 3G and 3H).
We further investigated the association of dysbiosis with
eczematous inflammation by performing protocol crossover
studies. A group of Adam17DSox9 mice was left untreated up to
week 10 after birth and then subsequently received antibiotic
therapy. Conversely, another group of Adam17DSox9 mice was
maintained on antibiotics from week 3 to 10, which were discon-
tinued thereafter (Figure S4A). Strikingly, initiation of antibiotics
in previously untreated Adam17DSox9 mice extinguished pre-
established eczematous dermatitis and inflammation (Figures4A-C and Figure S4A) and reversed dysbiosis (Figure 4D and
Figure S4B), indicating that targeting dysbiosis had a therapeutic
effect. Furthermore, although mice receiving continuous antibi-
otics were prevented from developing eczematous lesions, with-
drawal of antibiotics led to marked skin inflammation with rapid
emergence ofC. bovis and S. aureus (Figures 4A–4D and Figures
S4A and S4B). These data collectively establish dysbiosis as
a pivotal event during the onset of eczematous dermatitis in
Adam17DSox9 mice.
S. aureus and Corynebacterium Species Contribute to
Eczematous Dermatitis Formation
We next explored which of the three bacterial species that
constituted dysbiotic flora in Adam17DSox9 mice contributed to
the pathogenesis of eczematous inflammation. Meta-analysis
of clinical score, TEWL, and IgE in mice described in Figures 1
and 3 was performed. As anticipated from the association of
S. aureus in AD, and concordant with our observation that
S. aureus emerged immediately prior to the onset of eczematous
dermatitis (Figure S2D), formation of eczematous dermatitis in
Adam17DSox9 mice correlated with the proportion of S. aureus
and C. bovis (Figures S5A and S5B). IgE concentrations corre-
lated with only C. bovis frequency (Figure S5A). No positive
correlation of C. mastitidis with any of the factors studied herein
was found.
To assess the contribution of each bacterial species in vivo,
we utilized Adam17DSox9 mice that were pre-treated with antibi-
otics. Adam17DSox9 mice treated with the antibiotic cocktail
showed minimal signs of eczema (Figures S3A and S4A). After
termination of treatment, there exists an almost 2-week period
before overt appearance of eczematous dermatitis. Taking
advantage of this window, we inoculated SAAS9, CBAS9, or
a C. mastitidis strain (CMAS9, isolated from Adam17DSox9
mice) onto Adam17DSox9 mice immediately after termination of
antibiotics (Figure S5C). Strikingly, and consistent with the
meta-analysis, inoculation of mice with SAAS9 induced the
most severe eczematous dermatitis (Figures 5A and S5D). Inoc-
ulation of CBAS9 also induced enhanced eczematous derma-
titis, albeit to a lesser extent than SAAS9 (Figures 5A and
S5D). Clinical scores of mice that were inoculated with
CMAS9 were variable and did not reach statistical significance
when compared to un-inoculated control Adam17DSox9 mice
(Figures 5A and S5D).
T helper responses in skin-draining lymph nodes were
analyzed. Surprisingly, SAAS9-inoculation did not have an
impact on the numbers of Th1 or Th2 cells (Figure 5B). In
contrast, increased Th1 and Th2 responses, in particular the
latter, were observed in skin-draining lymph nodes of mice
inoculated with CBAS9 (Figure 5B). Although both SAAS9 and
CBAS9 showed trends for enhancing Th17 responses, they did
not reach not statistical significance. CMAS9 had no effect on
T helper responses that were analyzed.
These results identified S. aureus as potent inducer of eczem-
atous dermatitis via an immunological pathway that has yet to be
determined. C. bovis prominently enhanced Th2 responses,
providing explanation for elevated serum IgE concentrations
in Adam17DSox9 mice. Taken together, S. aureus and C. bovis
contribute to different aspects of eczematous inflammation in
this model.Immunity 42, 756–766, April 21, 2015 ª2015 Elsevier Inc. 759
Figure 3. Antibiotics Prevent Eczematous
Inflammation and Conserves Bacterial
Diversity
Adam17DSox9 mice were either treated or un-
treated with antibiotics cocktail (Abx) since wean-
ing. See also Figure S3.
(A–C) Clinical score, TEWL, and serum IgE con-
centrations (N = 7). Shown as mean ± SD. *p <
0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 as
determined by Student’s t test.
(D) Flow cytometry analysis of IFN-g, IL-4, and IL-
17A production in CD4+ cells from lymph nodes,
and (E) IL-17A and IL-22 production by CD3+ cells
in epidermis of WT and Adam17DSox9 mice (N = 7).
(F) Microbiota of Abx-treated and untreated
Adam17DSox9 andWTmice at indicated time points
after birth. Relative abundance plots of order-
genera that represented >1% of total 16S rRNA
gene sequences with additional speciation of
Corynebacterium and Staphylococcus genus of
four representative mice for each time point.
Results are representative of two experiments.
(G) Shannon diversity index of Abx-treated and
untreated Adam17DSox9 and WT mice from week 2
to 8 after birth. Each time point represents mean ±
SEM. *p < 0.05, **p < 0.01, ***p < 0.001 determined
by Student’s t test and adjusted for multiple com-
parison by Benjamini and Hochberg correction.
(H) Principal coordinates analysis (PCoA) of the mi-
crobial community structure (Theta similarity index)
of Abx-treated and untreatedAdam17DSox9 andWT
mice. A shorter distance between points indicates
higher similarity between the microbiome of sam-
ples represented by these points. Biplot arrows
indicate the twomost significant unique consensus
taxonomies contributing to variation along axes 1
and 2 as determined by Spearman correlation.
Length of biplot arrows reflects the contribution of
that taxa to the top two axes: a,S. aureus (r =0.73,
p < 1e-15); b, C. bovis (r = 0.77, p < 1e-15).
Spearman correlations and p values refer to axis 1.Ablation of EGFR-Signaling Allows Dysbiosis
Important roles of EGFR signaling in regulating skin immune ho-
meostasis have begun to be characterized, either in the context
of AD (Sa¨a¨f et al., 2012; Zhang et al., 2014) or EGFR-inhibitors
(Lacouture, 2006). EGFR ligands are major substrates of
ADAM17. ADAM17 cleaves the membrane-bound pro-forms of
EGFR ligands including heparin-binding EGF-like growth factor760 Immunity 42, 756–766, April 21, 2015 ª2015 Elsevier Inc.and TGF-a, and releases soluble forms
to activate EGFR signaling pathways. It
was recently shown that conditional abla-
tion of EGFR from epidermis led to a skin
inflammatory phenotype that was associ-
ated with barrier defects (Lichtenberger
et al., 2013; Mascia et al., 2013). We
therefore explored whether impaired
EGFR signaling downstream of ADAM17
contributed to dysbiosis and eczematous
dermatitis formation.
WegeneratedEgfrfl/flSox9-Cre (EgfrDSox9)
mice that did not express Egfr in Sox9-expressing tissues. Consistent with other reports, EgfrDSox9 mice
exhibited eczematous phenotypes thatwere similar to, but slightly
less severe than, those in Adam17DSox9 mice (Figures 6A and S6).
TEWLand serum IgE concentrationswere elevated in comparison
to WT mice (Figures 6B and 6C). Inflammatory profiles were also
similar to Adam17DSox9 mice, where EgfrDSox9 mice exhibited
mixed Th1, Th2, and Th17 accumulations in lymph nodes and
Figure 4. Antibiotics Have Therapeutic
Effect in Adam17DSox9 Mice
Adam17DSox9 mice were untreated from
39 weeks after birth, and were put on antibiotics
from 1013 weeks, or vice versa. See also
Figure S4.
(A and B) Clinical score and TEWL in Adam17DSox9
mice during the crossover protocol (N = 7).
(C) IL-17A and IL-22 production by CD3+ cells in
epidermis of Adam17DSox9 mice during the cross-
over protocol (N = 7).
(D) Relative abundance of order-genera that rep-
resented >1% of total 16S rRNA sequences with
additional speciation of Corynebacterium and
Staphylococcus genus before and after crossover.
The data in (A)(C) are shown as the mean ± SD.
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
determined by Student’s t test.Th17, Th22, and Tgd17 inflammation in skin (Figures 6D and 6E)
The numbers of IL-22-producing epidermal T cells were not as
prominent in EgfrDSox9 mice as in Adam17DSox9 mice (Figure 6E).
Skin swab cultures from 8-week-old EgfrDSox9 mice isolated
S. aureus (Figure 6F and 6G), and microbiome analysis revealed
the emergence of Corynebacterium spp and S. aureus (Fig-
ure 6H). Dysbiotic changes were less prominent than those
of Adam17DSox9 mice but nevertheless document impairment
of EGFR signaling as an important pathway downstream of
ADAM17 that allows the overgrowth of S. aureus and Coryne-
bacterium species.
Taken together, ADAM17 regulates homeostasis of cutaneous
microbial communities in an EGFR-dependent manner. Further
elucidation of mechanisms downstream of EGFR signaling
should provide information on molecules and cells that could
be considered to be potential targets to normalize dysbiosis.
Langerhans Cells Mediate Innate Responses to
S. aureus
In contrast to a colitis model in which gut dysbiosis and disease
can be transferred to co-housed WT mice (Elinav et al., 2011),
co-housing WT mice with Adam17DSox9 mice only led to tempo-
ral colonization of the former with S. aureus and did not transfer
skin disease (data not shown). This suggested that S. aureus
alone was insufficient to cause eczematous inflammation and
that it was incapable of persistently colonizing normal skin.
Therefore, to determine whether S. aureus could induce immune
responses through an impaired stratum corneum barrier, we uti-
lized Flg/ mice that have a defined barrier defect (Kawasaki
et al., 2012). Filaggrin is a major structural protein in the stratum
corneum, and FLG mutations are associated with human AD
(Palmer et al., 2006). However, Flg/mice do not develop spon-
taneous dermatitis under normal SPF conditions, but exhibit
enhanced percutaneous sensitization (Kawasaki et al., 2012).
Epidermal tight junctions are intact in these mice (unpublished
data).Immunity 42, 756–S. aureus (SAAS9) isolated from
Adam17DSox9 mice were topically inocu-
lated onto the shaved back skin of Flg/
and WT mice. Although topical inocula-tion did not induce overt dermatitis, it induced robust skin infiltra-
tion of Th17 and gdT17 cells into epidermis in Flg/, but not WT
mice (Figure 7A), demonstrating that barrier disruption in the
stratum corneum was sufficient for enhanced immune re-
sponses to topically inoculated S. aureus.
Langerhans cells (LCs) are unique dendritic cells in the
epidermis (Merad et al., 2008). Through a series of studies, we
have demonstrated that LCs take up microbial antigens that
have breached the stratum corneum, but exist outside of tight
junctions, by extending their dendrites through intact tight junc-
tion barrier and induce antigen-specific humoral (IgG1) re-
sponses (Nagao et al., 2009; Kubo et al., 2009; Ouchi et al.,
2011). When the epidermal barriers are breached during
Candida infection, LCs are capable of inducing Th17 responses
(Igya´rto´ et al., 2011).
During dysbiosis that occurs in stratum corneum (Figures
S2A-C), LCs are advantageously positioned to acquire those
bacteria through epidermal tight junctions. To determine
whether LCs contributed to immunity against S. aureus, we
generated Flg/ mice that lacked LCs, by crossing them to
mice that express diphtheria toxin fragment A driven by the hu-
man langerin promoter (Langerin-DTA mice) (Kaplan et al.,
2005). Of note, Th17 and gdT17 responses induced by topical
SAAS9-inoculation were abrogated in Flg/ Langerin-DTA
mice (Figure 7A), demonstrating a role for LC in mediating
IL-17 responses against S. aureus.
Because topical SAAS9 exposure did not generate dermatitis,
we inoculated SAAS9 via an occlusive dressing technique that
led to the formation of visible dermatitis in WT mice (Figure S7)
that lasted for approximately 3 days. Consistent with the immune
responses in the topical exposure protocol, dermatitis was
aggravated in Flg/ mice. However, dermatitis was attenuated
in Flg/ Langerin-DTA mice, and IL-17A responses were nearly
abrogated (Figures 7B and 7C and S7). IL-22 responses were not
observed in any setting (data not shown). The transient nature of
dermatitis in this assay indicates that S. aureus and barrier766, April 21, 2015 ª2015 Elsevier Inc. 761
Figure 5. Contribution of S. aureus, C. bovis
and C. mastitidis to Eczematous Inflam-
mation
After withdrawal of antibiotic treatment form
Adam17DSox9 mice that were pretreated with anti-
biotics,S. aureus,C.bovis, andC.mastitidis strains
were inoculated onto the mice. See also Figure S5.
(A) Clinical scores of Adam17DSox9 mice after
bacterial inoculation (N = 6–8).
(B) Flow cytometry analysis of IFN-g, IL-4, and
IL-17A production in CD4+ cells from lymph nodes
of bacteria-inoculated Adam17DSox9 mice (N =
6–8). The data are shown as the mean ± SD.
*p < 0.05, **p < 0.01, ***p < 0.001 determined by
Student’s t test.disruption are not sufficient to cause chronic disease. Neverthe-
less, these data demonstrated that LCs facilitated innate im-
mune responses against S. aureus, presumably by acquiring
components of S. aureus through the tight junction barrier.
This process likely represents an early immunological event in
the initial phases of dysbiosis and skin inflammation.
DISCUSSION
Eczematous inflammation in Adam17DSox9 mice occurred in
conjunction with a striking shift in microbiota, in which
S. aureus and Corybacterium spp were major constituents.
This dysbiotic pattern closely recapitulated those seen in human
AD (Kong et al., 2012) and primary immunodeficiencies with
eczematous dermatitis (Oh et al., 2013). In particular, S. aureus
colonization is universal in AD patients, and it has been long
debated whether emergence of S. aureus is a secondary by-
product of chronic inflammation or whether it is a primary
component of pathogenesis that actively contributes to eczema
development. In Adam17DSox9 mice, dysbiosis was a pivotal
event during eczematous dermatitis formation, and antibiotics-
mediated normalization of dysbiosis both prevented onset and
suppressed active inflammation. Furthermore, bacterial inocula-
tion experiments in Adam17DSox9 mice revealed that eczema-
tous inflammation could be accelerated by both S. aureus and
C. bovis (S. aureus > C. bovis). C. bovis was the only agent
that induced prominent Th2 responses, suggesting differential
contribution of S. aureus and C. bovis to the complex eczema-
tous phenotype. Generation of gnotobiotic mice would be
required to determine whether each agent is sufficient to induce
full-blown disease in the absence of each other and to determine
immunological pathways induced by S. aureus inoculation that
are critical for eczematous dermatitis formation. Although a
role for C. mastitidis was not revealed in the current study, it is
attractive to hypothesize that this organism might enhance the
growth of S. aureus and C. bovis.
The importance of IL-17 responses is well established in psori-
asis in bothmice andhumans (Lowes et al., 2014). Recent studies
report the involvement of IL-17 responses also in human AD
(Koga et al., 2008; Sua´rez-Farin˜as et al., 2013), but its relative
contribution to AD pathogenesis is not yet determined. Although
Adam17DSox9 mice did not exhibit macroscopic features that
were reminiscent of psoriasis, the robust IL-17 responsespromp-
ted us to exclude psoriatic inflammation. The lack of improve-
ment in Adam17DSox9 mice in both IL-17 and IL-23 backgrounds762 Immunity 42, 756–766, April 21, 2015 ª2015 Elsevier Inc.indicate that the pathophysiology of the skin inflammation is
distinct from that of psoriasis and that these cytokines are not
essential during an eczematous response. It is possible that the
IL-17 responses observed here arise secondarily to dysbiosis
and perhaps might be a consequence of utilizing mousemodels.
While mutations in the gene encoding the structural stratum
corneum protein Filaggrin are considered major predisposing
factors in ‘‘classic’’ AD (Irvine et al., 2011), a variety of other
genes are involved, and it is possible that further elucidation of
involved genes might subdivide this heterogeneous disease.
Whether or not eczematous dermatitis seen in Adam17DSox9
mice can be extrapolated to human diseases remains to be
determined. Importantly, the mouse model studied herein is an
actual counterpart of a rare human disease that manifests
eczematous dermatitis (Blaydon et al., 2011), and therefore
represents a prototypic eczematous dermatitis model. Dry
skin, pruritus, elevated serum IgE, and naturally occurring
dysbiosis in Adam17DSox9 mice recapitulate the most important
aspects of human eczematous dermatitis and AD.
A systematic review of human studies failed to provide strong
evidence for recommending interventions to reduce S. aureus in
AD (Bath-Hextall et al., 2010). However, outcomes of antibiotic
therapy in humans might be variable due to unconfirmed pres-
ence of dysbiosis at the start of the studies and as of yet subop-
timal combinations and/or dose of antibiotics. From this view-
point, future studies might require pre-treatment microbiome
analyses. Furthermore, intensified antibiotic cocktails might be
necessary to target skin-colonizing S. aureus, as is done for
Helicobacter pylori eradication (Chey and Wong, 2007; Malfer-
theiner et al., 2007). Thus, antibiotic data currently available for
humans is inconclusive and requires further evaluation.
We demonstrated that targeting dysbiosis via antibiotic
cocktails had dramatic effects on eczematous lesions of
Adam17DSox9 mice. However, administering an antibiotic cock-
tail for a prolonged period of time, as we have done experimen-
tally, is not likely to be a practical approach in patients. Long-
term oral antibiotic therapy would have undesirable effects on
microbiota in the gut and other distal sites (Cho et al., 2012;
Willing et al., 2011) and could also select antibiotic-resistant bac-
teria (Sommer and Dantas, 2011; Wright, 2007). Meanwhile,
bleach baths, a common clinical practice that is receiving
increasing scientific interest, is recommended for patients with
moderate to severe AD to reduce disease severity (Eichenfield
et al., 2014; Huang et al., 2009; Leung et al., 2013) and could
potentially be targeting dysbiosis. In combination with the
Figure 6. Ablation of EGFR-Signaling In-
duces Dysbiosis and Eczematous Inflam-
mation
(A) Clinical scores in Adam17DSox9 and EgfrDSox9
mice (N = 7). See also Figure S6.
(B and C) TEWL and serum IgE values in WT and
EgfrDSox9 mice (N = 7).
(D) Flow cytometry analysis of IFN-g, IL-4, and IL-
17A production in CD4+ cells from lymph nodes,
and (E) IL-17A and IL-22 production by CD3+ cells
in epidermis of WT and EgfrDSox9 mice (N = 7).
(F and G) Quantification of S. aureus cultured from
facial skin swab samples of WT and EgfrDSox9 mice
(N = 7).
(H) Microbiota of 8-week-old WT and Egfr17DSox9
mice.findings in the current work, mechanisms of this classic therapy
might deserve further exploration. The finding that dysbiosis oc-
curs in part via impaired EGFR signaling might provide founda-
tion for novel strategies to modify the skin microbiota.
In conclusion, the findings in this study document dysbiosis as
a pathological factor that can drive eczematous inflammation in
mice. Utilizing this unique model, it will be possible to further
explore molecular mechanisms in epidermis that result in dys-
biosis and inflammation, and to design strategies that normalize
them long-term. Accomplishment of these in a skin-specific
manner will lead to safe and effective therapies and should
have profound impact on the treatment of AD, as well as other
forms of eczematous dermatitis and perhaps skin rash associ-
ated with EGFR inhibitor use.
EXPERIMENTAL PROCEDURES
Details of experimental procedures on microbiome analysis are included in
Supplemental Information.
Mice
Adam17DSox9 mice and EgfrDSox9 mice were generated by crossing
Adam17flox/flox mice or Egfrflox/flox mice (kind gift from Dr. David Threadgill, Uni-
versity of North Carolina) with Sox9-Cre mice as previously described (Horiuchi
et al., 2009; Nagao et al., 2012).Micewere backcrossed into theC57BL/6 back-
ground for at least six generations. Il17/ and Il23p19/micewere generously
provided by Dr. A. Yoshimura (Keio University School of Medicine, Tokyo,
Japan). The generation of Flg/ mice and Langerin-DTA mice has beenImmunity 42, 756–described (Kaplan et al., 2005; Kawasaki et al.,
2012). All mice were bred and housed in a specific
pathogen free condition. All animal experimental
procedures and study protocols were approved
by the Ethical Committee for Animal Experiments
of the Keio University School of Medicine.
Preparation of Epidermal Cell Suspensions
Epidermal cell suspensions were prepared from
mouse trunk skin. Shaved trunk skin was incu-
bated with 0.15% trypsin and 0.27 mM EDTA at
37C for 45 min. Epidermal cells were scraped off
in 5% FBS PBS, washed and then filtered through
cell strainers (BD).
Flow Cytometry Analysis and Antibodies
For cytokine analysis, cell suspensions were incu-
bated for 5 hr in complete RPMIwith 50 ng/ml PMAand 500 ng/ml Ionomycin in the presence of 5 mg/ml Brefeldin A. Cells were
stained with LIVE/DEAD Fixable Dead Cell Stain Kits (Invitrogen) and surface
markers, followed by fixation and permeabilization with BD Cytofix/Cytoperm
(BD) and intracellular cytokine staining. The following antibodies from
BioLegend or eBioscience were used for analysis: anti-CD45 (30-F11), anti-
CD3 (145-2C11), anti-CD4 (GK1.5), anti-TCRgd (GL3), anti-IL-17A (TC11-
18H10.1), anti-IL-4 (11B11), anti-IFN-g (XMG1.2), and anti-IL-22 (1H8PWSR).
Antibiotic Treatment
Mice were treated with 0.5 mg/ml cefazolin (Nichi-Iko Pharmaceutical Co) and
0.5 mg/ml enrofloxacin (Bayer HealthCare) in drinking water.
Histological Analysis and Immunofluorescence Microscopy
Skin from the facial area of sacrificed mice was taken for hematoxylin and
eosin and toluidine blue staining. Immunofluorescence microscopy was per-
formed to detect S. aureus with biotinylated rabbit polyclonal anti-S. aureus
antibody (Abcam), which was detected with Alexa Fluor 488-conjugated
anti-biotin secondary antibody (Invitrogen).
Electron Microscopy
For scanning electron microscopy, skin taken from the facial area was fixed in
2% glutaraldehyde, post-fixed with osmium tetroxide, replaced with isoamyl
acetate and were observed by SV6600 (Hitachi). For transmission electron
microscopy, skin samples were pre-fixed with 2% glutaraldehyde, post-fixed
in osmium tetroxide, and were embedded in epoxy resin. Ultrathin sections
were prepared and were observed by JEM-1230 (JEOL).
IgE and Cytokine Analysis
Serum total IgE were measured by Mouse IgE ELISA quantitative set (Bethyl
Laboratories). Cytokine concentrations were measured by Milliplex Map Kit766, April 21, 2015 ª2015 Elsevier Inc. 763
Figure 7. Langerhans Cells Mediate IL-17 Response upon S. aureus
Inoculation
(A) Flow cytometry analysis of epidermis-infiltrating CD4 T cells and gd T cells
in topical inoculation of S. aureus on WT, Flg/, and Flg/ Langerin-DTA
mice (N = 6).
(B and C) Area of inflamed lesions and epidermis-infiltrating gd T cells of WT,
Flg/, and Flg/ Langerin-DTA mice inoculated with S.aureus via occlusive
dressing technique. The data are shown as themean ± SD. *p < 0.05, **p < 0.01
determined by Student’s t test. See also Figure S7.(Millipore), and serum CCL17/TARC was detected by Mouse CCL17/TARC
Quantikine (R&D Systems).
Clinical Score
Clinical severity of skin lesions was scored with a method adapted from a
scoring index of canine atopic dermatitis (Plant et al., 2012). In brief, the clinical
score was measured by assessing the severity and extent of lesions (ery-
thema, excoriation, erosion, alopecia, lichenification, and hyperpigmentation)
at head and pinnae, forefeet, hind feet, ventral thorax and axillae, ventral
abdomen and inguinal, and graded as 0 (none), 1 (mild), 2,3 (moderate), or
4,5 (severe and extensive lesions). The total index ranges from 0 to 50.
Trans Epidermal Water Loss
TEWL was measured with a VAPOSCAN AS-VT100RS machine (Asahi
Biomed).764 Immunity 42, 756–766, April 21, 2015 ª2015 Elsevier Inc.Bacterial Culture
Cultures were obtained with swabs from a cheek of mice and plated on
Mannitol salt agar with egg yolk (BD) or Trypticase soy agar with 5% sheep
blood (BD). To measure CFUs of S. aureus, we performed a standard plate
count method. Briefly, skin swabs from a cheek of mice (1 cm2) were placed
into 1 ml of PBS, and serial dilutions were prepared. 100 ml of each dilution
was transferred on Mannitol salt agar with egg yolk plates (BD), and colonies
were counted after 2-day incubation. CFUs were calculated by dividing the
number of colonies per plate by the dilution factor.
Bacterial Isolation and Inoculation onto Adam17DSox9 Mice
C. mastitidis and C. bovis were isolated from Adam17DSox9 mice on
Trypticase soy agar with 5% sheep blood plates (BD), and S. aureus was
isolated by culturing on Mannitol salt agar with egg yolk plates (BD), for
consistency. Isolated strains were designated as SAAS9 (S. aureus),
CBAS9 (C. bovis), and CMAS9 (C. mastitidis). All analyzed S. aureus isolates
had sequences that were identical to that of ST88 clone via multilocus
sequence typing (MLST) (http://saureus.mlst.net), therefore likely represent-
ing a single clone. Ten colonies of each bacteria species were picked and
dissolved in 0.4 ml sterile PBS. Bacteria containing PBS or control PBS
were inoculated with cotton swabs on facial area of mice. The mice were
pre-treated with antibiotics from 3 weeks after birth to 8–10 weeks, and
inoculation of bacteria was started after withdrawal of antibiotic treatment.
The inoculation was performed from day 0 to day 6, and the mice were
analyzed on day 8.
SAAS9 Inoculation onto Flg–/– Mice
SAAS9 was placed into tryptic soy broth (BD) and grown overnight at
37C in a shaking incubator. Exponential-phase bacteria were obtained
after a 1-hr subculture of a 1:50 dilution of the overnight culture. Bacterial
concentrations were estimated by measuring the absorbance of at
600 nm. Bacterial cells were pelleted and washed 3 times in PBS. 4 3
107 colony forming units of SAAS9 in 100 ml of PBS were topically inoculated
on shaved back skin of mice. SAAS9 inoculation was performed at days 1,
3, 5, 7, and 9, and the mice were examined at day 10. For inoculation via
occlusive dressing, 4 3 107 CFUs of SAAS9 were applied, and the back
skin of mice was covered with TegadermTM Roll (Sumitomo 3M Limited).
The dressing was removed at day 4, and the mice were examined at day
7. Area of skin lesions were photographed and measured by Photoshop
CS5.1 (Adobe).
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